CENCORA INC

Investors cheer Cencora Inc.’s new $2 billion share‑repurchase and stronger 2026 earnings outlook, boosting its lead in high‑margin, tech‑driven healthcare delivery.

Wells Fargo cuts Cencora’s target after Lasix ONYU launch: learn why the drug‑device combo’s pricing, regulatory risks and at‑home care trend drive a 12% hit to investor upside.

Q1 2026 update: Cencora’s solid liquidity, 3.5% gross‑margin growth, and AI‑powered supply‑chain gains show a pharmacy‑distribution firm boosting profits and shareholder value in a regulated market.

How Cencora’s Nottingham hub closure boosts margins, cuts CAPEX and fuels global growth in pharma distribution.

Discover how Cencora’s partnership with SQ Innovation and FIS will launch Lasix ONYU, a cutting‑edge home‑care drug‑device combo, boosting specialty pharma distribution worldwide.

Explore how Cencora’s $1.1 B acquisition of EyeSouth’s retina business expands eye‑care distribution, boosts supplier leverage, and improves patient access to retinal therapies.

Discover how Cencora Inc.’s strategic growth and innovation propelled its post‑IPO stock to impressive gains, boosting shareholder value and market confidence.

Explore how Cencora Inc.’s CFO retirement and strategic focus on tech‑driven value‑based care shape its growth and resilience in today’s evolving healthcare market.

Read how Cencora’s partnership with Acclinate’s NOWINCLUDED platform boosts inclusive clinical trials, diversifying data, accelerating approvals, and driving ESG value.

Explore Cencora Inc.’s dividend hike, market performance vs. the S&P 500, and how QIVIGY®’s nationwide launch reflects broader pharma growth.